Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure

• Status: Recruiting
• Trial end date: 2025-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the study is to compare short-term (8 weeks) anticoagulation therapy (DOAC) vs. antiplatelet therapy for the prevention of device thrombosis following transcatheter LAAC.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
• Treatments: Apixaban; Aspirin; Clopidogrel; Dabigatran; Edoxaban; Rivaroxaban

Criteria

Inclusion Criteria:

• Successful transcatheter LAAC with any approved device

• Age≥18 years old

Exclusion Criteria:

• Absolute contraindications for anticoagulation therapy

• Prior intracranial hemorrhage

• Contraindications for TEE

• Severe pericardial effusion within the first 24 hrs following LAAC

• Major/life-threatening bleeding within the first 24 hrs following LAAC

• Female subjects of childbearing potential without using highly effective methods of contraception